The short answer
Melatonin can cause drowsiness, so review it with your prescriber when taking ropinirole. The combination has not been shown to require a particular dose interval or a change in melatonin need. Small Parkinson disease trials also found improved sleep outcomes.
What this answer covers
Oral melatonin; licensed prolonged-release instructions and trial doses are preparation-specific.
- Supplement or preparation
- Melatonin
- Medication ingredient
- ropinirole
Why alertness matters
Melatonin can cause drowsiness, and ropinirole can cause sleepiness or sudden sleep episodes. Review the combination if you already feel sleepy or take other sedating medicines. The amount of any extra risk has not been measured.
What Parkinson disease trials found
Two small trials found improved subjective sleep outcomes with melatonin. The newer trial also found improved daytime sleepiness scores. These results argue against assuming that everyone becomes sleepier, but the accessible reports do not establish an effect specifically in ropinirole users.
Timing depends on the product and treatment plan
The bedtime instructions for licensed prolonged-release melatonin belong to that product. They do not establish an interval from ropinirole or show that ropinirole changes your need for melatonin. Ask your pharmacist to review the exact formulation and reason for use.
When daytime sleepiness needs attention
Contact your prescriber promptly for new marked daytime sleepiness or falling asleep during ordinary activities. Do not drive or use machinery if this occurs. Ropinirole can cause sleep episodes even without a warning feeling of drowsiness; the treating team should decide how to change treatment.
Evidence and practical considerations
Side effects & toxicity
A conditional alertness precaution is supported, but altered melatonin requirements and a pair-specific timing rule are not established.
- Exact scope
- Oral melatonin; licensed prolonged-release instructions and trial doses are preparation-specific. with Oral immediate-release ropinirole, with hydrochloride salt expressed as equivalent free base in label section 11.
- Medication form and route
- oral
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- No verified ropinirole-specific subgroup or controlled exact-pair exposure analysis.
Factors that may matter: baseline alertness; exact preparation; other medicines; treatment indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
No direct study of these six supplement combinations. Immediate-release tablet context does not establish release-form or dose interchangeability.
Source 2: product label
medicines.org.uk · Source check Sep 10, 2026
Population: People considering the specified supplement.
Can cause drowsiness and impair driving. Bedtime instructions are specific to this prolonged-release preparation. Co-administration with zolpidem increased impairment, but that is a different medicine.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
No ropinirole study. Findings with zolpidem or this licensed formulation cannot define every melatonin product or a protective interval.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 86 people with Parkinson disease randomized; 73 completed.
Subjective sleep quality and daytime sleepiness scores improved relative to placebo; reported side effects were minimal.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Exact ropinirole co-exposure not verified in accessible abstract. Authors caution about clinical importance and generalizability from relatively young, shorter-duration disease with modest levodopa-equivalent exposure.
Source 4: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 18 people with Parkinson disease.
Subjective sleep quality improved; polysomnography and motor outcomes did not significantly improve.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Small sample; exact ropinirole co-exposure not verified from abstract. Does not establish changed melatonin requirements or a pair-specific interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Targeted sources inspected and all current available claims adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: a58b6e5e311416ef
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.